Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 2/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | AIMP2 | Q13155 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1043944 | 0.83 | CA2 (0.51) | CA2DRD2LTA4HFFAR1ALOX5 | |
| SCHEMBL17272731 | 0.83 | CA2 (0.51) | CA2DRD2LTA4HFFAR1ALOX5 | |
| SCHEMBL29444757 | 0.83 | CA2 (0.51) | CA2DRD2LTA4HFFAR1ALOX5 | |
| SCHEMBL9205454 | 0.83 | CA2 (0.55) | CA2DRD2LTA4HFFAR1ALOX5 | |
| SCHEMBL9212404 | 0.83 | CA2 (0.55) | CA2DRD2LTA4HFFAR1ALOX5 | |
| SCHEMBL29481769 | 0.83 | CA2 (0.51) | CA2DRD2LTA4HFFAR1ALOX5 | |
| SCHEMBL1043824 | 0.83 | CA2 (0.51) | CA2DRD2LTA4HFFAR1ALOX5 | |
| SCHEMBL17272730 | 0.83 | CA2 (0.51) | CA2DRD2LTA4HFFAR1ALOX5 | |
| SCHEMBL9213269 | 0.83 | CA2 (0.55) | CA2DRD2LTA4HFFAR1ALOX5 | |
| SCHEMBL8282396 | 0.81 | CA2 (0.59) | CA2FFAR1MEN1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9416138-B2 | Benzyl sulfonamide compounds useful as MoGAT-2 inhibitors | ELI LILLY AND COMPANY (US) | 2016-08-16 | — | — | US | disclosed |
| US-20150284404-A1 | NOVEL BENZYL SULFONAMIDE COMPOUNDS USEFUL AS MOGAT-2 INHIBITORS | ELI LILLY AND COMPANY | 2015-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284404-A1 | NOVEL BENZYL SULFONAMIDE COMPOUNDS USEFUL AS MOGAT-2 INHIBITORS | MOGAT2, SOAT1, SOAT2 | CA2 2070/4885DRD2 4622/4885LTA4H 2034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.